Post-hoc Analysis: Evaluating the Timing and Magnitude of Control of Disease Activity with Aflibercept 8mg and Faricimab for nAMD
Key Three Year Results from the PHOTON Extension Study
Intraocular Pressure Outcomes with Intravitreal Aflibercept 8mg and 2mg in Patients with nAMD and DME in Phase III Trials
Post-hoc Analysis of Reduction in Epithelial Detachments with Faricimab vs. Aflibercept in Patients with Treatment-Naive nAMD
Analysis of PULSAR and PHOTON 2-Year Data Presented at AAO
Pooled Safety Analysis of Aflibercept 8mg in the CANDELA, PHOTON, and PULSAR Trials Presented at the Retina Society
Baseline Characteristics of Patients Who Did or Did Not Maintain 12- and 16-Week Aflibercept 8mg Dosing Intervals in the Phase 2/3 PHOTON Trial in Patients with DME
Clinical Outcomes of DME Patients with Baseline Visual Acuity of 20/50 or Worse Treated with Faricimab and Aflibercept in the YOSEMITE/RHINE Clinical Trials: A Pooled Subcohort Analysis in Patients with DME
Analysis of Intervention Arms in the PULSAR Trials and BCVA Gains Through 96-Weeks
Analysis of the 48 and 96-week Outcomes from the PHOTON Trial
Impact of Baseline Central Retinal Thickness on Visual and Anatomic Outcomes in Patients with DME: a Post Hoc Analysis of the Phase 2/3 PHOTON Trial
Analyzing Two Year Data from the PULSAR Phase III Study and Clinical Implications
Analysis of a PULSAR Subgroup Analysis: Aflibercept 8mg Efficacy in CNV Subtypes Including PCV Over 96 Weeks with Ability to Extend Dosing Intervals to >16 Weeks
Post-hoc Analysis of Phase III Studies of Faricimab Evaluating Retinal Drying
2-Year Data from Registration Trials of Faricimab in nAMD and DME
Post-hoc analysis of the YOSEMITE and RHINE Trials in DME
12-month Real-World Clinical Outcomes with Faricimab in Patients with nAMD: The FARETINA-AMD Study
Emerging Data around Emerging Tyrosine Kinase Inhibitors for the Treatment of nAMD
